ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis

Cancer Gene Therapy

Volumn 12, Issue 1, 2005, Pages 61-71

  Yun, Chae Ok ^a   Kim, Eunhee ^a   Koo, Taeyoung ^a   Kim, Hoguen ^b   Lee, Young Sook ^a   Kim, Joo Hang ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Adenovirus; ADP; Apoptosis

Indexed keywords

ADENOVIRUS VECTOR; LIPOCORTIN 5; ONCOLYTIC VIRUS; VIRUS PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CYTOLYSIS; CYTOMEGALOVIRUS; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NICK END LABELING; PRIORITY JOURNAL; PROMOTER REGION; SKIN FIBROBLAST; STAINING; TRANSCRIPTION INITIATION; TUMOR CELL LINE; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE; VIRUS PLAQUE; VIRUS REPLICATION; XENOGRAFT;

ADENOVIRIDAE; ADENOVIRUS E3 PROTEINS; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FIBROBLASTS; GENE THERAPY; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; VIRUS REPLICATION;

ADENOVIRIDAE; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 10844281217     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700769     Document Type: Article

References (34)

1. Kim D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene. 2000;19:6660-6669.
2. Kim D. Oncolytic virotherapy for cancer with the adenovirus d11520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther. 2001;1:525-538.
3. Kirn D. Clinical research results with d11520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Therapy. 2001;8:89-98.
4. Lee H, Kim J, Lee B, et al. Oncolytic potential of E1B 55 kDa-deleted YKL-1 recombinant adenovirus: correlation with p53 functional status. Int J Cancer. 2000;88:454-463.
5. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55 kDa gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000;60:6359-6366.
6. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6:798-806.
7. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000;18:609-622.
8. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879-885.
9. Lament JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol. 2000;7:588-592.
10. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995;69:2004-2015.
11. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A. 1995;92:1401-1405.
12. Wold WS, Tollefson AE, Hermiston TW. E3 transcription unit of adenovirus. Curr Top Microbiol Immunol. 1995;199(Part 1):237-274.
13. Paabo S, Bhat BM, Wold WS, Peterson PA. A short sequence in the COOH-terminus makes an adenovirus membrane glycoprotein a resident of the endoplasmic reticulum. Cell. 1987;50:311-317.
14. Burgert HG, Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell. 1985;41:987-997.
15. Shisler J, Yang C, Walter B, Ware CF, Gooding LR. The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J Virol. 1997;71:8299-8306.
16. Zanardi TA, Yei S, Lichtenstein DL, Tollefson AE, Wold WS. Distinct domains in the adenovirus E3 RIDalpha protein are required for degradation of Fas and the epidermal growth factor receptor. J Virol. 2003;77:11685-11696.
17. Tollefson AE, Hermiston TW, Lichtenstein DL, et al. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature. 1998;392:726-730.
18. Krajcsi P, Dimitrov T, Hermiston TW, et al. The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J Virol. 1996;70: 4904-4913.
19. Gooding LR, Elmore LW, Tollefson AE, Brady HA, Wold WS. A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell. 1988;53: 341-346.
20. Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol. 1999;11:380-386.
21. Horwitz MS. Adenovirus immunoregulatory genes and their cellular targets. Virology. 2001;279:1-8.
22. Mahr JA, Gooding LR. Immune evasion by adenoviruses. Immunol Rev. 1999;168:121-130.
23. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol. 1996;70:2296-2306.
24. Tollefson AE, Scaria A, Saha SK, Wold WS. The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J Virol. 1992;66:3633-3642.
25. Kim J, Cho JY, Kim JH, Jung KC, Yun CO. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther. 2002;9:725-736.
26. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 1996;70:4805-4810.
27. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995;182:1545-1556.
28. Wold WS, Cladaras C, Magie SC, Yacoub N. Mapping a new gene that encodes an 11,600-molecular-weight protein in the E3 transcription unit of adenovirus 2. J Virol. 1984;52:307-313.
29. Scaria A, Tollefson AE, Saha SK, Wold WS. The E3-11.6K protein of adenovirus is an Asn-glycosylated integral membrane protein that localizes to the nuclear membrane. Virology. 1992;191:743-753.
30. Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WS. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology. 1996;220:152-162.
31. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 2000;74:6147-6155.
32. Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol. 2001;75: 3314-3324.
33. Habib NA, Mitry R, Seth P, et al. Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Ther. 2002;9:651-654.
34. Ramachandra M, Rahman A, Zou A, et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol. 2001;19:1035-1041.